Results 91 to 100 of about 139,183 (310)

Ageing and Autoantibodies

Autoimmunity, 1988
Immune responsiveness decreases with age, while the production of autoantibodies increases, indicating that these are end results of perturbations in the regulatory mechanisms of the immune system. The effects of ageing on the immune system are reviewed.
Yaron Tomer, Yehuda Shoenfeld
openaire   +3 more sources

Obliterative portal venopathy: A neglected and probably misdiagnosed disease with peculiar etiology in South America

JGH Open, Volume 6, Issue 12, Page 904-909, December 2022., 2022
Classically described in the group of non‐cirrhotic portal hypertension, obliterative portal venopathy (OPV) causes are still unknown. Our aim is to describe the characteristics of 43 OPV patients and potential risk factors. Clinically significant portal hypertension was found in 28% of cases. The most frequent indication for liver biopsy was elevation
Vinícius Nunes, Luiz A R de Freitas, Juliana R de Freitas, Caio Araújo, Gildásio N Junior, Maria I Schinoni, Fernando Bessone, Raymundo Paraná   +7 more
wiley   +1 more source

Autoantibody pain

Autoimmunity Reviews, 2016
As autoantibodies bind to target tissues, Fc-region dependent inflammation can induce pain via mediators exciting nociceptors. But recently another possibility has emerged, where autoantibody binding to nociceptors can directly cause pain, without inflammation.
openaire   +2 more sources

Role of STING Deficiency in Amelioration of Mouse Models of Lupus and Atherosclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a systemic autoimmune syndrome characterized by autoreactive responses to nucleic acids, dysregulation of the type I interferon (IFN‐I) pathway, and accelerated atherosclerosis. The stimulator of IFN genes (STING), a cytosolic DNA sensor, has pathogenic implications in various inflammatory diseases ...
Yudong Liu, Carmelo Carmona‐Rivera, Nickie L. Seto, Christopher B. Oliveira, Eduardo Patino‐Martinez, Yvonne Baumer, Tiffany M. Powell‐Wiley, Nehal Mehta, Sarfaraz Hasni, Xuan Zhang, Mariana J. Kaplan   +10 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source

Editorial: Autoantibodies [PDF]

Frontiers in Immunology, 2019
Holmdahl, Rikard, Nimmerjahn, Falk, Ludwig, Ralf J.   +2 more
openaire   +3 more sources

Studies on Autoantibodies in Human Sera [PDF]

, 1953
Alexander S. Wiener, Eve B. Gordon, Carol Gallop   +2 more
openalex   +1 more source

Evaluating Renal Disease in Pediatric‐Onset Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome

Arthritis &Rheumatology, EarlyView.
Objective We aimed to study the disease course, outcomes, and predictors of outcome in pediatric‐onset antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) affecting the kidneys. Methods Patients eligible for this study had a diagnosis of granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or ANCA‐positive pauci‐immune ...
Kirandeep K. Toor, Audrea Chen, David A. Cabral, Cherry Mammen, Else S. Bosman, Ye Shen, Jeffrey N. Bone, Damien Noone, Eslam Al‐Abadi, Susanne Benseler, Roberta Berard, Marek Bohm, Sirirat Charuvanij, Kathryn Cook, Paul Dancey, Samundeeswari Deepak, Ciaran Duffy, Barbara Eberhard, Melissa Elder, Dirk Foell, Dana Gerstbacher, Merav Heshin‐Bekenstein, Adam Huber, Karen E. James, Susan Kim, Marisa Klein‐Gitelman, Neil Martin, Flora McErlane, L. Nandini Moorthy, Charlotte Myrup, Phil Riley, Susan Shenoi, Vidya Sivaraman, Tamara Tanner, Stacey Tarvin, Linda Wagner‐Weiner, Rae S. M. Yeung, Kelly L. Brown, Kimberly A. Morishita, on behalf of the PedVas Investigators Network   +39 more
wiley   +1 more source

Identification of Intrinsic Factor Autoantibody and Intrinsic Factor in Man by Radioimmunodiffusion and Radioimmunoelectrophoresis [PDF]

, 1965
I. Michael Samloff, Eugene V. Barnett
openalex   +1 more source

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial

Arthritis &Rheumatology, EarlyView.
Objective Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSCs) compared with monthly cyclophosphamide (CY).
George E. Georges, Dinesh Khanna, Mark H. Wener, Matthew G. Mei, Maureen D. Mayes, Robert W. Simms, Vaishali Sanchorawala, Chitra Hosing, Suzanne Kafaja, Attaphol Pawarode, Leona A. Holmberg, Jason Kolfenbach, Daniel E. Furst, Keith M. Sullivan, Suiyuan Huang, Ted Gooley, Richard A. Nash   +16 more
wiley   +1 more source